Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06567795 · ClinicalTrials.gov registry record
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
A clinical trial of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by Aventusoft.
- Recruiting
- Registry status
- 189
- Enrollment target
- 1
- Study location
NCT06567795: Recruiting study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, sponsored by Aventusoft.
NCT06567795 is a study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases that is actively recruiting participants, run by Aventusoft. The registered enrollment target is 189 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06567795, a study of Diabetes Mellitus, Type 2 and Cardiovascular Diseases, is actively recruiting participants, sponsored by Aventusoft.
- RECRUITING
- Registry status
- 189 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
Primary Outcome
The primary endpoint will be to evaluate CV events measured by a composite endpoint defined by unplanned hospitalizations, emergency room visits/urgent care visits (that do not result in hospitalization), for cardiovascular events or death within the observation period of 12 months.
Conditions Studied
Interventions
- DEVICE Hemotag
Study Locations (1)
Florida
- Metabolic Research Institute, Inc - West Palm Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2024-03-14 |
| Est. Completion | 2027-03-18 |
What NCT06567795 shows while recruiting
NCT06567795 is an observational study that tracks outcomes without assigning an intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Hemotag is the first listed.
NCT06567795 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06567795 about?
NCT06567795 is a clinical study titled "PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG". To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
What is the current status of trial NCT06567795?
This trial is currently recruiting. The enrollment target is 189 participants. The study started on 2024-03-14. Estimated completion is 2027-03-18.
What conditions does trial NCT06567795 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Coronary Artery Disease, Peripheral Artery Disease, Cerebrovascular Disease.
What interventions are being tested in trial NCT06567795?
The interventions under investigation include: Hemotag (DEVICE).
Who is sponsoring clinical trial NCT06567795?
This trial is sponsored by Aventusoft, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06567795 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06567795's enrollment target sits among peer trials
189 160th of 348 higher than 189 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI